Optimization of acid suppression for patients with peptic ulcer bleeding
Göran Hasselgren(AstraZeneca (Sweden)), A. B. R. Thomson(University of Iowa), M. Keelan(Alberta Hospital Edmonton), P Kirdeikis(Alberta Hospital Edmonton), Paul Sinclair, Joanna Lee, Kerstin Röhss(AstraZeneca (Sweden))
Cited by 44
Related Papers
World Gastroenterology Organisation Global Guidelines
|Journal of Clinical Gastroenterology|2014|521
Pharmacokinetics and pharmacodynamics of esomeprazole, the S‐isomer of omeprazole
|Alimentary Pharmacology & Therapeutics|2001|175
Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects
|European Journal of Clinical Pharmacology|2000|140
Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole
|British Journal of Clinical Pharmacology|1998|124
Effect of Esomeprazole 40 mg vs Omeprazole 40 mg on 24-Hour Intragastric pH in Patients with Symptoms of Gastroesophageal Reflux Disease
|Digestive Diseases and Sciences|2002|93